Drug class/drug |
Dose |
Nucleoside RTIs |
Zidovudine (ZDV) |
300 mg twice daily |
Stavudine (d4T) |
40 mg twice daily
(30 mg twice daily if <60 kg) |
Lamivudine (3TC) |
150 mg twice daily |
Didanosine (ddI) |
400 mg once daily
(250 mg once daily if < 60 kg) |
Abacavir (ABC) |
300 mg twice daily |
Nucleotide RTI |
Tenofovir (TDF) |
300 mg once daily |
Non-nucleoside RTIs |
Efavirenz (EFZ) |
600 mg once daily |
Nevirapine (NVP) |
200 mg once daily for 14 days, then
200 mg twice daily |
Protease inhibitors |
Nelfinavir (NFV) |
1250 mg twice daily |
Indinavir/ritonavir (IDV/r) |
800 mg/100 mg twice dailyb, c |
Lopinavir/ritonavir (LPV/r) |
400 mg/100 mg twice daily
(533 mg/133 mg twice daily when combined with EFZ or NVP) |
Saquinavir/ritonavir (SQV/r) |
1000 mg/100 mg twice dailyc, d |
a The doses listed are those for individuals with normal renal and hepatic function. Product-specific information should be consulted for dose adjustments that may be indicated for renal or hepatic dysfunction or for potential drug interactions with other HIV and non-HIV medications.
b This dosage regimen is not approved but supportive data exist and the regimen is in common clinical use. Other IDV/r dosage regimens that range from 800 mg/200 mg twice daily to 400 mg/100 mg twice daily are also in clinical usage but more data are needed to determine the optimal dose combination.
c Dosage adjustment when combined with an NNRTI is indicated but a formal recommendation cannot be made at this time. One consideration is to increase the RTV component to 200 mg twice daily when EFZ or NVP is used concomitantly. More drug interaction data are needed.
d This dosage regimen is not approved but supportive data exist for its use. Both the hard-gel and soft-gel capsule formulations can be used when SQV is combined with RTV.
Loading...
